KLOW RESULTS · RESEARCH RECORD
KLOW Results in the Research Literature
A component-by-component reading of what the published studies have actually measured — the recent results first, the honest absence named plainly.
In plain English
KLOW results in the research literature are, strictly speaking, four separate sets of results — one for each peptide component — not one unified set of blend-level results. No controlled study has ever measured outcomes for the KLOW four-peptide blend against a control, against monotherapy or against a subset. All combination result claims are extrapolations from single-component preclinical data. This page assembles the most important results from each arm's literature, names the most recent papers first, and holds the structural absence plainly: the result of testing the blend itself is an empty table. The component results are real and worth reading. The blend table is empty and that is also real.
KPV results
The foundational KPV result is from Dalmasso et al. 2008 [3]: nanomolar KPV (10 nM) inhibited NF-kappaB and MAP-kinase signaling and reduced TNF-alpha, IL-6, IL-1beta and IL-8 in human intestinal epithelial cells; oral KPV at 100 µM reduced DSS- and TNBS-induced colitis severity in C57BL/6 mice. PepT1 (SLC15A1) mediates uptake at a substrate Km of approximately 160 µM.
The most recent KPV result: the 2024 PepT1-targeted nanodrug study [8] showed that co-assembly of KPV with FK506 into targeted nanoparticles improved both acute and chronic colitis in mice, restoring tight-junction proteins and reducing inflammatory cytokines beyond either agent alone — the most advanced demonstration to date of KPV's anti-inflammatory potential in a delivery-optimized context.
For gut-delivery infrastructure, Laroui et al. 2010 [9] showed that polysaccharide-hydrogel-encapsulated nanoparticles delivered to the colon reduced colitis in mice, establishing the oral delivery strategy later adapted for KPV.
GHK-Cu results
GHK-Cu has the longest clinical data record in the blend. The 2015 Pickart et al. review [4] documents: collagen production increased in 70% of women treated with topical GHK-Cu versus 50% for vitamin C and 40% for retinoic acid; documented placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density. Plasma GHK declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60.
The 2018 gene-expression analysis [5] showed GHK at 1–10 nM modulates approximately 31.2% of human genes at a 50%-or-greater change threshold, with strongest signals toward the ubiquitin-proteasome system (41 genes up), DNA-repair and antioxidant programs.
Most recent GHK-Cu results: the 2025 Mao et al. colitis study [11] showed GHK-Cu reduced colonic damage and cytokines via SIRT1/STAT3 pathway suppression, restoring epithelial barrier function. The 2025 Mortazavi et al. anti-wrinkle delivery review [12] synthesizes topical GHK-Cu efficacy and the formulation/penetration challenge. Hair-follicle stimulation was reported for topical peptide-copper complexes in C3H mice [15].
BPC-157 results
The canonical BPC-157 result is from Staresinic et al. 2003 [2]: intraperitoneal BPC-157 at 10 µg, 10 ng or 10 pg per Wistar rat accelerated healing of a fully transected Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte outgrowth in vitro. A 2006 follow-up [10] showed BPC-157 also promoted tendon-to-bone healing after Achilles detachment and counteracted corticosteroid impairment.
Most recent BPC-157 results: the 2025 first-in-human IV safety pilot [6] — 10 mg day one, 20 mg day two in two healthy adults — found no adverse events and no measurable changes in safety biomarkers. Small n; not efficacy data. The 2026 Int J Mol Sci review [7] synthesizes the regenerative and analgesic findings and places analgesia as a primary theme of the accumulated record.
TB-500 results
The foundational result for the TB-500 arm is from Malinda et al. 1999 [1], using full-length thymosin beta-4: topical or intraperitoneal Tbeta4 increased rat full-thickness wound re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline; as little as 10 pg stimulated keratinocyte migration 2–3-fold in vitro; wound contraction increased ≥11% by day 7.
Most recent result: Wei et al. 2024 [13] showed inhaled exogenous thymosin beta-4 suppressed bleomycin-induced pulmonary fibrosis in a preclinical model — extending the tissue-repair record from dermal wounds to lung. The 2026 Mendias and Awan sports-medicine review [14] concludes that unapproved peptides including TB-500 show animal-model promise but scarce rigorous human safety data, with potential for serious harm.
The key caveat, restated: all significant TB-500 arm results are for the full-length 43-amino-acid native protein thymosin beta-4, not the short Ac-LKKTETQ TB-500 fragment. The fragment's efficacy relative to the native protein has not been formally established.
The absent blend result
No controlled study has tested the KLOW four-peptide blend. The KPV + GHK-Cu + BPC-157 + TB-500 combination has never appeared in a study design — no randomized trial, no animal model, no in-vitro experiment comparing the blend against monotherapy, against a three-peptide subset or against a vehicle control. The KLOW results table at the blend level is empty. This is the central fact. The component records are substantial; combining them in one vial does not generate blend-level evidence by extension. Whether the combination rationale holds — that four non-overlapping mechanism arms address complementary steps of the same cascade synergistically — remains an open experimental question.